



January 3, 2017

Genomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 3, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that [Kim Popovits](#), chairman of the board, chief executive officer and president, will present at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 9, 2017 at 11:00 a.m. Pacific Time.

To access the live and subsequently archived webcast of the presentation, go to the [Investor Relations](#) section of the company's web site at <http://investor.genomichealth.com>. Please connect to the web site at least 15 minutes prior to the presentation to allow for any software download that may be necessary. An archived replay will be available for three months beginning 24 hours after the live presentation.

About Genomic Health

[Genomic Health](#), Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 700,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select assay. The company is based in [Redwood City](#), California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: [@GenomicHealth](#), [Facebook](#), [YouTube](#) and [LinkedIn](#).

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

GHDX-F



To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/genomic-health-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-300383964.html>

SOURCE Genomic Health, Inc.

News Provided by Acquire Media